Pronounce: SI-pu-LOO-sel tee
Classification: Autologous Cellular Immunotherapy
Sipuleucel-T is a type of immunotherapy. Immunotherapy medications stimulate (rev up) your body's immune system to attack cancer cells. Sipuleucel-T is tailor-made specifically for your body from your own immune cells. Immune cells are first collected from the patient and exposed to a protein that "teaches" the immune cells to target the cancer cells. These immune cells are then given back to the patient to help treat the cancer.
Sipuleucel-T is given by intravenous (IV, into a vein) infusion. Prior to each dose, you may be given medications, including acetaminophen and an antihistamine (such as diphenhydramine), to decrease the risk of an infusion reaction.
A few days prior to each dose, the patient must undergo collection of their immune cells, which will be used to make that dose. This is done by leukapheresis, a procedure that is similar to dialysis or platelet donation. The immune cells are sent to a processing facility, where they are combined with an immune cell activator called granulocyte-macrophage colony-stimulating factor (GM-CSF), and then returned to the cancer center for infusion.
There are a number of things you can do to manage the side effects of sipuleucel-T. Talk to your care team about these recommendations. They can help you decide what will work best for you. These are some of the most common side or effects:
Sipuleucel-T stimulates the immune system, much like a flu virus would, and expected side effects are related to this stimulation. Often called "flu-like symptoms", these include chills, fever, fatigue, achy joints and muscles, and headache. Talk to your healthcare team about using acetaminophen or ibuprofen to manage these symptoms. They typically last only a few days after the infusion.
The infusion can cause a reaction. Symptoms of an infusion reaction include: fever, chills, low blood pressure, racing heart, shortness of breath, flushing, swelling of the throat or face, abdominal or back pain, nausea, and vomiting. You will receive Tylenol and diphenhydramine prior to the infusion to help prevent these reactions. Some patients will also receive a steroid before the infusion to prevent a reaction. Most patients can resume the infusion at a slower rate. It is possible to have a reaction up to one day after the infusion, so be sure to notify your healthcare provider if you experience any symptoms.
Fatigue is very common during cancer treatment and is an overwhelming feeling of exhaustion that is not usually relieved by rest. While on cancer treatment, and for a period after, you may need to adjust your schedule to manage fatigue. Plan times to rest during the day and conserve energy for more important activities. Exercise can help combat fatigue; a simple daily walk with a friend can help. Talk to your healthcare team for helpful tips on dealing with this side effect.
Talk to your oncology care team so they can prescribe medications to help you manage nausea and vomiting. In addition, dietary changes may help. Avoid things that may worsen the symptoms, such as heavy or greasy/fatty, spicy or acidic foods (lemons, tomatoes, oranges). Try saltines, or ginger ale to lessen symptoms.
Call your oncology care team if you are unable to keep fluids down for more than 12 hours or if you feel lightheaded or dizzy at any time.
It has not been studied if exposure of an unborn child to this medication could cause birth defects, so you should not father a child while on this medication. Effective birth control is necessary during treatment. Even if you believe you are not producing sperm, you could still be fertile.
OncoLink is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through OncoLink should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem or have questions or concerns about the medication that you have been prescribed, you should consult your health care provider.
Information Provided By: www.oncolink.org | © 2025 Trustees of The University of Pennsylvania